Validation of Sequential ROX-Index Score Beyond 12 Hours in Predicting Treatment Failure and Mortality in COVID-19 Patients Receiving Oxygen via High-Flow Nasal Cannula.
Journal
Canadian respiratory journal
ISSN: 1916-7245
Titre abrégé: Can Respir J
Pays: Egypt
ID NLM: 9433332
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
09
2022
revised:
25
12
2022
accepted:
25
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
High-flow nasal cannula (HFNC) is an oxygen delivery method shown to reduce the risk of intubation and mortality in patients with type 1 respiratory failure. The ROX-index score can predict HFNC failure. This study aims to evaluate sequential ROX-index assessments as predictors of HFNC failure and mortality. Prospective observational single-center study including all adult patients with positive SARS-CoV-2 PCR placed under HFNC from 1st November 2020 to 31st May 2021, and patients with hemodynamic instability or unable to tolerate HFNC were excluded. The primary endpoint was successful HFNC de-escalation. In univariate analysis, HFNC de-escalation was associated with younger age (59.2 ± 14 vs. 67.7 ± 10.5 and ROX-index is proven to be a valuable and easy-to-use tool for clinicians in the assessment of COVID-19 patients under HFNC.
Sections du résumé
Background
High-flow nasal cannula (HFNC) is an oxygen delivery method shown to reduce the risk of intubation and mortality in patients with type 1 respiratory failure. The ROX-index score can predict HFNC failure. This study aims to evaluate sequential ROX-index assessments as predictors of HFNC failure and mortality.
Methods
Prospective observational single-center study including all adult patients with positive SARS-CoV-2 PCR placed under HFNC from 1st November 2020 to 31st May 2021, and patients with hemodynamic instability or unable to tolerate HFNC were excluded. The primary endpoint was successful HFNC de-escalation.
Results
In univariate analysis, HFNC de-escalation was associated with younger age (59.2 ± 14 vs. 67.7 ± 10.5 and
Conclusion
ROX-index is proven to be a valuable and easy-to-use tool for clinicians in the assessment of COVID-19 patients under HFNC.
Identifiants
pubmed: 36817550
doi: 10.1155/2023/7474564
pmc: PMC9931457
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7474564Informations de copyright
Copyright © 2023 Dimitris Basoulis et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Am J Respir Crit Care Med. 2017 May 1;195(9):1128-1131
pubmed: 28459344
Respir Care. 2010 Apr;55(4):408-13
pubmed: 20406507
Crit Care. 2021 Feb 11;25(1):58
pubmed: 33573680
Intensive Care Med. 2015 Apr;41(4):623-32
pubmed: 25691263
Crit Care. 2019 Nov 27;23(1):374
pubmed: 31775846
BMC Pulm Med. 2020 Dec 24;20(1):324
pubmed: 33357219
Adv Respir Med. 2021;89(1):1-7
pubmed: 33471350
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376
pubmed: 30576221
J Pers Med. 2021 Sep 30;11(10):
pubmed: 34683130
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908
Crit Care Explor. 2020 Oct 21;2(10):e0254
pubmed: 33134945
BMJ. 2021 Mar 10;372:n436
pubmed: 33692022
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Dis Mon. 1994 Nov;40(11):581-638
pubmed: 7924834
Crit Care. 2021 Mar 25;25(1):121
pubmed: 33766109
Ann Intensive Care. 2013 May 10;3(1):12
pubmed: 23663301
Crit Care Med. 2016 Jan;44(1):120-9
pubmed: 26474112
J Crit Care. 2021 Dec;66:102-108
pubmed: 34507079
Anesthesiology. 2020 Jun;132(6):1317-1332
pubmed: 32195705
Respir Med. 2021 Aug-Sep;185:106474
pubmed: 34044293
Minerva Cardiol Angiol. 2021 Oct;69(5):596-605
pubmed: 33059400
J Crit Care. 2016 Oct;35:200-5
pubmed: 27481760